查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117002

口服補體抑制劑市場：依藥物、年齡層、通路、類型、給藥途徑、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Oral Complement Inhibitors Market, By Drug, By Age Group, By Distribution, By Type, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，口服補體抑制劑市場價值將達到 21.807 億美元，從 2026 年到 2033 年將以 7.1% 的複合年成長率成長。

口服補體抑制劑是標靶治療，可透過口服給藥抑制特定的補體蛋白。在諾華的產品系列中，iptacopan 是唯一口服補體抑制劑。其適應症涵蓋多種血液系統疾病、腎臟疾病、眼科疾病和免疫系統疾病。這些產品採用合成製程、生物製藥生產、無菌填充和包裝以及藥物遞送技術進行生產。到 2025 年，諾華的藥物將惠及全球 3.04 億患者。因此，市面上提供了種類繁多的注射用和玻璃體內注射用補體抑制劑，涵蓋相似的適應症和治療方法。此外，市場趨勢正在推動針對不同適應症的口服療法的研發，單藥治療通常更受青睞，以實現長期疾病管理。

口服補體抑制劑市場－市場動態

選擇性路徑控制正在重新定義補體療法的作用。

通路選擇性抑制正將補體療法從廣泛的末端抑制轉向與疾病生物學機制更密切相關的干預措施。伊普他可泮（Iptacopan）標靶替代途徑中的因子B，並作為一種口服藥物，用於治療多種以此替代途徑放大為特徵的疾病，包括陣發性睡眠性血紅蛋白尿症（PNH）、IgA腎臟病和C3腎小球病（C3G）。憑藉其上游作用機制，伊普他可泮不僅可以取代靶向C5的抗體，還可以實現長期門診治療。在III期APPEAR-C3G試驗中，諾華公司報告稱，到2025年，蛋白尿減少了35.1%，這支持了近端補體抑制的臨床效用。隨著通路特異性療法療效的證據日益清晰，基於作用機制的差異化在市場開發中將變得越來越重要。

口服補體抑制劑市場－市場區隔分析：

全球口服補體抑制劑市場按藥物、年齡層、分銷、類型、給藥途徑和地區進行細分。

在同類藥物中，iptacopan 是唯一的口服治療藥物，這是其市場地位的關鍵特徵。作為首個口服 B 因子抑制劑，它靶向替代補體途徑，為血液系統疾病和腎臟疾病提供治療選擇，同時避免了患者使用需要定期靜脈輸注的 C5 標靶療法。此外，2025 年 3 月，FDA 批准 Fabharta 用於治療 C3G，使 iptacopan 可治療的補體介導疾病總數達到三種。因此，研發重點正從針對單一疾病轉向建構一個能夠治療多種補體介導疾病的口服平台。

然而，其他補體抑制劑，例如Eculizumab、拉維珠單抗、斯替利單抗、培塞他可普蘭和阿巴辛卡帕德聚乙二醇，預計也將繼續在更廣泛的補體療法市場中佔據重要地位。截至2025年，Aperis公司報告稱，培塞他可普蘭在所有已通過核准適應症中的患者暴露時間已超過2200人年，這表明該公司在腸外補體抑制劑方面擁有豐富的臨床經驗。因此，口服補體療法將在商業性和臨床層面面臨現有藥物的競爭。此外，生物製藥公司在相容性和與生物相似藥的競爭方面也將面臨額外的實際挑戰。

口服補體抑制劑市場—區域分析

北美在治療藥物市場佔據強勢地位，這得益於其完善的罕見疾病生態系統、高標準的醫療保健、臨床研究以及快速的監管流程。 Fabhalta於2025年3月在美國獲準用於治療C3G，成為首個獲準用於治療該疾病的藥物，顯著擴大了口服途徑選擇性補體抑制劑的市場。此外，EMPAVELI於2025年7月在美國核准用於治療C3G和原發性免疫複合物性膜增生性腎絲球腎炎（IC-MPGN）。 2025年美國核准的藥物對市場產生了重大影響。促成美國市場領先地位的關鍵因素包括監管的影響力及其對競爭療法臨床開發的影響、核准流程所需證據的有效性以及對後續療法商業化的連鎖反應。

歐洲是至關重要的輔助療法市場，其特點是法規環境協調良好、罕見疾病患者網路龐大，以及對藥品進行嚴格評估。 2025年2月，歐洲藥品管理局（EMA）人用藥品委員會（CHMP）對用於治療C3G的藥物Fabharta發布了積極的審查意見。同時，諾華公司指出，該疾病患者中有一半會在確診後10年內發展為腎衰竭。因此，該疾病帶來的沉重負擔推動了對緩解疾病療法的需求，並凸顯了統一的臨床和監管監督的必要性。然而，儘管監管審查結果良好，但各國的報銷政策和商業性環境仍有差異。因此，歐洲不僅是輔助銷售市場，更是選擇性補體抑制療法檢驗和准入的關鍵市場，發揮至關重要的作用。

目錄

第1章：口服補體抑制劑市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：口服補體抑制劑的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：口服補體抑制劑的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：口服補體抑制劑市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：口服補體抑制劑的市場趨勢

  • 口服補體抑制劑市佔率分析（2025年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 口服補體抑制劑市場：依藥物分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類型
    • Eculizumab
    • 伊普塔科潘
    • 蒸氣清除器
    • 洛維茲瑪
    • 佩格塞塔科計劃
    • 阿巴辛卡普塔德·佩戈爾
    • 其他

第8章 口服補體抑制劑市場：依年齡層別分類

  • 概述
    • 按年齡層分類的市佔率分析
    • 成人
    • 兒童

第9章 口服補體抑制劑市場：依通路分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 藥局和零售藥房
    • 醫院藥房
    • 網路藥房
    • 專科藥房
    • 其他

第10章 口服補體抑制劑市場：依類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按類型
    • 生物相似藥
    • 品牌
    • 其他

第11章 口服補體抑制劑市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 靜脈
    • 玻璃體內注射
    • 皮下
    • 其他

第12章 口服補體抑制劑市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章：主要供應商分析：口服補體抑制劑產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Akari Therapeutics, Plc
    • Alexion Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals, Inc.
    • Biocryst Pharmaceuticals, Inc.
    • Amgen Inc.
    • ChemoCentryx, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Omeros Corporation
    • Roche Holding AG
    • Swedish Orphan Biovitrum AB
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7273

Oral Complement Inhibitors Market size was valued at US$ 2,180.7 Million in 2025, expanding at a CAGR of 7.1% from 2026 to 2033.

Oral complement inhibitors are targeted therapies that suppress specific complement proteins via oral administration, with iptacopan being the only orally administered complement inhibitor in the provided portfolio. The indications range from various hematologic, nephrologic, ocular, and immunologic disorders. It is produced through synthetic processes, biologics manufacturing, sterile fill-finish, and drug delivery technologies. Novartis's medicines reached 304 million patients worldwide in 2025. Thus, the market provides a wide range of complement inhibitors for injectable and intravitreal administration, covering similar indications and therapies. Moreover, the market trends towards developing oral therapies for diverse indications while generally favoring single-agent regimens that provide long-term disease control.

Oral Complement Inhibitors Market- Market Dynamics

Selective Pathway Control Is Rewriting Complement-Therapy Positioning

Pathway-selective inhibition is changing complement therapy from broad terminal blockade toward intervention closer to disease biology. Iptacopan targets factor B in the alternative pathway and has shown growth as an oral therapy for a range of diseases, including PNH, IgA nephropathy, and C3G, which are characterized by alternative pathway-driven amplification. With an upstream mechanism of action, iptacopan not only provides an alternative to C5-targeting antibodies but also allows for chronic outpatient therapy. In the Phase III APPEAR-C3G trial, Novartis reported a 35.1% reduction in proteinuria in 2025, supporting the clinical utility of proximal complement inhibition. As the evidence for the therapeutic benefit of pathway-specific approaches emerges, the need for differentiation based on the mechanism of action will become important to market development.

Oral Complement Inhibitors Market- Segmentation Analysis:

The Global Oral Complement Inhibitors Market is segmented on the basis of Drug, Age Group, Distribution, Type, Route of Administration, and Region.

Within the drug category, iptacopan is positioned as the only oral therapy, which addresses the key attribute of the market. Being the first oral inhibitor of factor B, it targets the alternative complement pathway and provides treatment options for both hematological and renal diseases while sparing patients the need for C5-directed therapeutics that require regular infusions. Moreover, in March 2025, the FDA approved Fabhalta for the treatment of C3G, making iptacopan the third complement-mediated disease to be addressed by the drug. Hence, the focus shifts to the oral platform that can offer treatment across a range of complement-mediated diseases rather than targeting individual conditions.

However, other complement inhibitors, including eculizumab, ravulizumab, sutimlimab, pegcetacoplan, and avacincaptad pegol, are expected to retain significant relevance in the broader complement therapeutics market. As of 2025, more than 2,200 patient-years of exposure to pegcetacoplan have been reported across Apellis' approved indications, illustrating the depth of clinical experience with non-oral complement inhibitors. As such, orally administered complement therapeutics will face competition from established agents on both commercial and clinical grounds-with biologics presenting additional practical challenges in terms of interchangeability and biosimilar competition.

Oral Complement Inhibitors Market- Geographical Insights

North America is well positioned in the therapeutics market due to a sophisticated rare disease ecosystem, high levels of care, clinical research, and fast regulatory processes. The U.S. approved Fabhalta for C3G in March 2025, making it the first treatment for the disease and significantly bolstering the market for oral pathway-selective complement inhibitors. In the U.S., EMPAVELI received approval for the treatment of C3G and primary IC-MPGN in July 2025. The approvals in the U.S. in 2025 could significantly impact the market. The key factors for the U.S. leading the market are the influence of its regulatory authorities and the subsequent impact on the clinical development of rival therapeutics, as well as the relevance of the evidence required for the approval process and the implications for the commercialization of later-line treatments.

Europe is an important complement therapy market, dominated by a coordinated regulatory environment, rare-disease patient networks, and critical evaluation of drugs. In February 2025, the EMA's CHMP gave Fabhalta a positive opinion for C3G, while Novartis has noted that half of patients with the disease will develop kidney failure within a decade of diagnosis. Thus, the considerable burden of illness drives demand for disease-modifying treatments, supporting the need for centralized clinical and regulatory oversight. However, reimbursement decisions are nationally differentiated, defining the commercial landscape despite favorable regulatory reviews. Europe therefore functions as a critical validation and access market for selective complement inhibition rather than merely a secondary sales territory.

Oral Complement Inhibitors Market- Competitive Landscape:

The factors that determine competitive dynamics within the oral complement therapeutics market are mechanism of action, route of administration, indication, and evidence of clinical efficacy. Novartis sells Fabhalta, which is administered orally and targets factor B. It competes with AstraZeneca's C5 portfolio and Apellis's C3 inhibitor, pegcetacoplan. Novartis has reported that its drugs were distributed in 118 countries worldwide in 2025. The company has an organized framework for commercializing its pharmaceuticals on a global scale. The other competitive factors that could impact market growth are manufacturing, pharmacovigilance, vaccination, specialty distribution, and patient identification by indications. The competitive landscape is therefore shifting towards diversity of platforms and lifecycle management, with oral selectivity as a key differentiator.

Recent Developments:

In March 2025, the FDA approved Novartis's Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G). Fabhalta became the first and sole therapy for patients with C3G, an ultra-rare kidney disease, which was previously poorly addressed by available treatments.

In July 2025, Apellis Pharmaceuticals announced the approval of its EMPAVELI (pegcetacoplan) for the treatment of C3G and primary IC-MPGN. The Phase III VALIANT study of EMPAVELI showed a 68% decrease in proteinuria along with C3 reduction, stabilization of kidney function, and reduction of C3 deposits.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • Amgen Inc.
  • ChemoCentryx, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Omeros Corporation
  • Roche Holding AG
  • Swedish Orphan Biovitrum AB
  • Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033

  • Eculizumab
  • Iptacopan
  • Sutimlimab
  • Ravulizumab
  • Pegcetacoplan
  • Avacincaptad pegol
  • Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033

  • Adults
  • Pediatric

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies
  • Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Biosimilar
  • Branded
  • Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Intravenous
  • Intravitreal
  • Subcutaneous
  • Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Oral Complement Inhibitors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oral Complement Inhibitors Market Snippet by Drug
    • 2.1.2. Oral Complement Inhibitors Market Snippet by Age Group
    • 2.1.3. Oral Complement Inhibitors Market Snippet by Distribution
    • 2.1.4. Oral Complement Inhibitors Market Snippet by Type
    • 2.1.5. Oral Complement Inhibitors Market Snippet by Route of Administration
    • 2.1.6. Oral Complement Inhibitors Market Snippet by Country
    • 2.1.7. Oral Complement Inhibitors Market Snippet by Region
  • 2.2. Competitive Insights

3. Oral Complement Inhibitors Key Market Trends

  • 3.1. Oral Complement Inhibitors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oral Complement Inhibitors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oral Complement Inhibitors Market Opportunities
  • 3.4. Oral Complement Inhibitors Market Future Trends

4. Oral Complement Inhibitors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oral Complement Inhibitors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Oral Complement Inhibitors Market Landscape

  • 6.1. Oral Complement Inhibitors Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oral Complement Inhibitors Market - By Drug

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug, 2025 & 2033 (%)
    • 7.1.2. Eculizumab
    • 7.1.3. Iptacopan
    • 7.1.4. Sutimlimab
    • 7.1.5. Ravulizumab
    • 7.1.6. Pegcetacoplan
    • 7.1.7. Avacincaptad pegol
    • 7.1.8. Others

8. Oral Complement Inhibitors Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2025 & 2033 (%)
    • 8.1.2. Adults
    • 8.1.3. Pediatric

9. Oral Complement Inhibitors Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
    • 9.1.2. Drug Stores & Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies
    • 9.1.5. Specialty Pharmacies
    • 9.1.6. Others

10. Oral Complement Inhibitors Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
    • 10.1.2. Biosimilar
    • 10.1.3. Branded
    • 10.1.4. Others

11. Oral Complement Inhibitors Market - By Route of Administration

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 11.1.2. Intravenous
    • 11.1.3. Intravitreal
    • 11.1.4. Subcutaneous
    • 11.1.5. Others

12. Oral Complement Inhibitors Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Oral Complement Inhibitors Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Oral Complement Inhibitors Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.18. Denmark
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Denmark Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.19. Rest of Europe
      • 12.3.19.1. Overview
      • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Oral Complement Inhibitors Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.17. Taiwan
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Taiwan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.18. Vietnam
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.18.3. Vietnam Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.18.4. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.18.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.18.6. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.18.7. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.19. Rest of APAC
      • 12.4.19.1. Overview
      • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.19.3. Rest of APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.4.19.4. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.4.19.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.4.19.7. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Oral Complement Inhibitors Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Oral Complement Inhibitors Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.15. Iran
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Iran Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.16. Qatar
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.16.3. Qatar Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.16.4. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.16.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.16.6. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.16.7. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.17. Rest of MEA
      • 12.6.17.1. Overview
      • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.17.3. Rest of MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 12.6.17.4. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
      • 12.6.17.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 12.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 12.6.17.7. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Oral Complement Inhibitors Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Akari Therapeutics, Plc
    • 13.2.2. Alexion Pharmaceuticals, Inc.
    • 13.2.3. Apellis Pharmaceuticals, Inc.
    • 13.2.4. Biocryst Pharmaceuticals, Inc.
    • 13.2.5. Amgen Inc.
    • 13.2.6. ChemoCentryx, Inc.
    • 13.2.7. Ionis Pharmaceuticals, Inc.
    • 13.2.8. Johnson & Johnson Services, Inc.
    • 13.2.9. Merck & Co., Inc.
    • 13.2.10. Novartis AG
    • 13.2.11. Pfizer Inc.
    • 13.2.12. Regeneron Pharmaceuticals, Inc.
    • 13.2.13. Omeros Corporation
    • 13.2.14. Roche Holding AG
    • 13.2.15. Swedish Orphan Biovitrum AB
    • 13.2.16. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us